Intake Forms for Substance Abuse Counseling: A Complete Guide for Addiction Treatment Providers
No area of clinical practice carries higher documentation stakes than substance abuse and addiction counseling. The intake process for a new client entering substance use disorder treatment is not merely an administrative formality — it is a clinical assessment, a legal safeguard, a regulatory compliance event, and often the first moment of genuine human connection in what may be a court-ordered, family-pressured, or crisis-driven entry into care. Get it wrong, and you risk misplacing a client on the continuum of care, violating federal confidentiality protections that are stricter than HIPAA, or missing a co-occurring condition that will derail treatment within the first two weeks.
This guide covers every section that a substance abuse counseling intake form should include, why each one matters from both a clinical and compliance perspective, and how to structure the documentation so that it protects the client, the counselor, and the program.
Why Substance Abuse Intake Forms Are Different
Before getting into the sections themselves, it is worth understanding why addiction treatment intake forms carry unique requirements that other behavioral health practices do not face.
First, substance use disorder records are governed by 42 CFR Part 2, a federal regulation that imposes confidentiality protections beyond what HIPAA requires. Under Part 2, a program cannot even acknowledge that a person is a patient without the individual's written consent. This means the intake form must include a consent architecture that most mental health or medical practices never think about.
Second, addiction treatment spans a wider continuum of care than almost any other clinical specialty. A single intake may need to determine whether the client belongs in medical detoxification, residential treatment, intensive outpatient, standard outpatient, or medication-assisted treatment — and the clinical and insurance implications of that placement decision are enormous. The ASAM Criteria (American Society of Addiction Medicine) provides the framework, but the intake form is where you collect the data that drives the placement.
Third, a significant percentage of clients entering substance abuse treatment are doing so under some form of external pressure — a court order, a child protective services mandate, a professional licensing board requirement, or an employer's last-chance agreement. These clients bring legal documentation that must be integrated into the intake process, and the treatment program takes on reporting obligations that require their own consent forms and tracking mechanisms.
Fourth, the medical acuity at intake can be high. Clients may present in active withdrawal, with overdose histories, with infectious disease exposure, or with medication regimens (methadone, buprenorphine, naltrexone) that require immediate coordination with prescribers. The intake form needs to capture enough medical information to triage safely.
Substance Use History and Pattern Documentation
The substance use history is the clinical core of the addiction intake form, and it needs to be substantially more detailed than the substance use screening section on a general mental health intake. This is not a "do you drink?" checkbox — this is a comprehensive inventory of the client's relationship with every substance they have used, organized in a way that reveals patterns, progression, and current severity.
Structured Substance-by-Substance Inventory
The most effective format is a grid or table that lists each substance category and captures, for each one: age of first use, age of regular use, route of administration (oral, intranasal, intravenous, smoked, sublingual), frequency of current use, quantity per use episode, date of last use, and whether the client has ever experienced withdrawal symptoms from that substance.
The substance categories should include at minimum: alcohol, cannabis, cocaine/crack, heroin, prescription opioids (specify), methamphetamine/amphetamines, benzodiazepines (specify), barbiturates, hallucinogens (LSD, psilocybin, MDMA), inhalants, synthetic cannabinoids, fentanyl (listed separately from other opioids given its prevalence and lethality), nicotine/tobacco, caffeine, and an open field for any substance not listed.
Two details that many intake forms miss and should not: route of administration and fentanyl as a separate line item. Route matters because intravenous use carries infectious disease risk (hepatitis B, hepatitis C, HIV) that triggers additional screening requirements, and because it is a marker of severity that affects level-of-care determination. Fentanyl deserves its own line because clients who believe they are using heroin, cocaine, or counterfeit pills may be unknowingly using fentanyl, and the withdrawal profile, overdose risk, and medication-assisted treatment protocol differ significantly.
Validated Screening Instruments
In addition to the substance-by-substance inventory, many programs embed one or more validated screening tools directly into the intake form or append them as scored addenda. The most commonly used instruments include:
- AUDIT (Alcohol Use Disorders Identification Test) — A 10-item screener developed by the World Health Organization. Scores of 8 or above suggest hazardous or harmful alcohol use; scores of 20 or above suggest probable dependence. The shorter AUDIT-C (3 items) works as a rapid screen. These are useful at intake because they produce a quantifiable severity score that can be tracked across treatment.
- DAST-10 (Drug Abuse Screening Test) — A 10-item yes/no screener covering the past 12 months of drug use. Scores of 1-2 suggest low severity, 3-5 moderate, 6-8 substantial, and 9-10 severe. The DAST is especially useful for identifying clients who minimize their drug use during the interview but will answer honestly on a written screener.
- CAGE Questionnaire — Four questions (Cut down, Annoyed, Guilty, Eye-opener) that take less than a minute. Two or more positive answers suggest a clinically significant alcohol problem. The CAGE is quick enough to include on any intake form, but it has limitations — it was developed primarily for detecting alcohol dependence in medical settings and is less sensitive to hazardous drinking patterns or drug use.
- CAGE-AID — An adapted version of the CAGE that broadens the questions to include drug use alongside alcohol, making it more appropriate for substance abuse treatment settings where polysubstance use is the norm rather than the exception.
- ASI (Addiction Severity Index) — A longer, semi-structured interview that assesses seven domains: medical, employment, drug use, alcohol use, legal, family/social, and psychiatric. The ASI is more of a comprehensive assessment than a screening tool, but some programs use it as the backbone of the intake process itself.
The choice of screening instrument matters less than the consistency with which it is used. Pick one or two, embed them into the intake workflow, and score them every time. A scored AUDIT or DAST at intake gives you a baseline against which to measure treatment progress — and it gives payers a quantifiable justification for the level of care you are recommending.
42 CFR Part 2 Confidentiality: What Your Intake Form Must Include
If you run a substance use disorder treatment program — or even if you are a solo practitioner who holds yourself out as providing substance abuse diagnosis, treatment, or referral — you are almost certainly a "Part 2 program" subject to 42 CFR Part 2. This regulation, originally enacted in the 1970s to encourage people to seek addiction treatment without fear that their records would be used against them in criminal proceedings, imposes confidentiality requirements that go substantially beyond HIPAA.
Key Part 2 Requirements That Affect the Intake Form
- Prohibition on re-disclosure. When you share a client's substance use records with an outside party, that party is prohibited from re-disclosing the information to anyone else. Every consent form authorizing disclosure must include a re-disclosure prohibition notice, and the notice language is specified by the regulation.
- Written consent for any disclosure. Unlike HIPAA, which permits disclosure for treatment, payment, and healthcare operations without individual authorization, Part 2 historically required written consent for virtually every disclosure. The 2024 amendments aligned Part 2 more closely with HIPAA for treatment, payment, and operations — but many states have not yet updated their own laws, and the consent form architecture at intake still needs to account for both the federal and state requirements.
- No acknowledgment of patient status. A Part 2 program cannot confirm or deny that a particular individual is or has been a patient, even to law enforcement, without the individual's consent or a court order that meets specific regulatory requirements. This means your intake form consent section must explicitly address whether the client authorizes the program to communicate with outside parties at all.
- Qualified Service Organization Agreements (QSOAs). If your program uses outside vendors (billing companies, labs, EHR providers) that will have access to patient-identifying information, you need QSOAs with those vendors — the Part 2 equivalent of HIPAA Business Associate Agreements, but with additional restrictions.
Consent Form Architecture at Intake
At a minimum, the intake packet for a Part 2 program should include:
- A general consent to treatment that includes an acknowledgment that the client's records are protected by federal confidentiality regulations (42 CFR Part 2) and cannot be disclosed without written consent.
- A specific consent for each entity the program needs to communicate with — referral source, primary care provider, psychiatrist, probation officer, family member, employer, child protective services. Each consent must name the recipient, the purpose of the disclosure, the specific information to be disclosed, the expiration date, and the client's right to revoke the consent at any time.
- A Notice of Federal Requirements informing the client that their records are protected under Part 2, that violations can be reported to the U.S. Attorney, and providing the required re-disclosure prohibition language.
The practical implication is that the consent section of a substance abuse intake form is often three to four pages long — substantially longer than the consent section for a general therapy practice. This is not overlawyering. It is a federal requirement, and programs that cut corners on Part 2 consent face real regulatory exposure.
ASAM Criteria and Level of Care Determination
The ASAM Criteria is the national standard for matching clients to appropriate levels of addiction treatment. Your intake form needs to collect sufficient data across all six ASAM dimensions to support a defensible placement decision:
- Dimension 1: Acute Intoxication and/or Withdrawal Potential. Current substances in the client's system, time since last use, history of withdrawal seizures or delirium tremens, CIWA-Ar or COWS scores if obtainable at intake.
- Dimension 2: Biomedical Conditions and Complications. Current medical conditions, medications, infectious disease status, pregnancy, chronic pain conditions, and any acute medical needs that would affect treatment placement.
- Dimension 3: Emotional, Behavioral, or Cognitive Conditions. Co-occurring mental health disorders, current psychiatric medications, history of psychiatric hospitalization, current suicidal or homicidal ideation, cognitive impairments.
- Dimension 4: Readiness to Change. Where the client falls on the stages-of-change continuum (precontemplation, contemplation, preparation, action, maintenance). Whether the client is entering treatment voluntarily or under mandate. Motivation level and perceived barriers to treatment.
- Dimension 5: Relapse, Continued Use, or Continued Problem Potential. Number of prior treatment episodes, relapse history, identified triggers, longest period of sustained sobriety, current coping strategies.
- Dimension 6: Recovery/Living Environment. Housing stability, sober living situation, presence of substance-using individuals in the home, employment status, transportation access, childcare needs, social support network quality.
The intake form does not need to replicate the full ASAM assessment — that is the clinician's job in the biopsychosocial assessment that follows — but it needs to capture enough self-reported data across all six dimensions that the clinician can begin forming a placement recommendation before the first face-to-face assessment concludes. Failure to document ASAM-aligned data is the single most common reason that insurance companies deny authorization for higher levels of care.
Detoxification Screening and Medical Clearance
Clients who present for substance abuse treatment may need medical detoxification before they can safely participate in psychosocial treatment. The intake form must screen for withdrawal risk factors that determine whether the client needs medical monitoring during the detoxification period:
- Alcohol withdrawal risk: Duration and quantity of daily alcohol consumption, history of prior withdrawal episodes, history of withdrawal seizures or delirium tremens (DTs), last drink date and time, current BAC if obtainable. Alcohol withdrawal is potentially fatal — a client who reports a history of seizures or DTs during prior withdrawal attempts requires medical detoxification, not social detoxification or cold-turkey abstinence in an outpatient setting.
- Benzodiazepine withdrawal risk: Similar to alcohol withdrawal in severity and lethality. Duration and dosage of benzodiazepine use, whether prescribed or illicit, last dose date and time. Benzodiazepine withdrawal can produce seizures and should be managed medically.
- Opioid withdrawal risk: While opioid withdrawal is rarely life-threatening in otherwise healthy adults, it is intensely uncomfortable and a primary driver of relapse. The intake form should capture the type of opioid (heroin, fentanyl, prescription opioids), route, daily quantity, and last use. Fentanyl withdrawal deserves special attention because fentanyl's long tissue half-life can produce protracted withdrawal symptoms and complicates the timing of buprenorphine induction.
- Stimulant withdrawal: Cocaine and methamphetamine withdrawal is not medically dangerous but can produce severe depression, hypersomnia, and suicidal ideation that require monitoring.
- Polysubstance use: Clients using multiple substances simultaneously (for example, alcohol and benzodiazepines, or opioids and stimulants) present compounded withdrawal risk. The intake form should flag polysubstance use patterns clearly so the medical team can plan accordingly.
The intake form should also include a medical history section sufficient for medical clearance: current medications, known allergies, chronic conditions (liver disease, cardiovascular conditions, diabetes, seizure disorders, HIV/hepatitis status), current pregnancy or possibility of pregnancy, and date of last physical examination.
Co-Occurring Mental Health Disorder Assessment (Dual Diagnosis)
The co-occurrence of substance use disorders and mental health disorders is the rule, not the exception. Research consistently shows that approximately half of individuals with a substance use disorder also meet criteria for at least one co-occurring mental health condition, and the actual rate in treatment-seeking populations is likely higher. Depression, anxiety disorders, PTSD, bipolar disorder, ADHD, and personality disorders are the most common co-occurring conditions in substance abuse treatment settings.
The intake form needs to screen for co-occurring disorders with enough specificity to guide initial treatment planning. A single checkbox that says "mental health history: yes/no" is inadequate. Instead, include:
- Prior mental health diagnoses — with a checklist of the most common co-occurring conditions and an open field for others.
- Current psychiatric medications — name, dosage, prescribing provider, and whether the client is taking them as prescribed. Many clients entering substance abuse treatment have stopped taking their psychiatric medications, and the intake form is where you discover this.
- History of psychiatric hospitalization — dates, facilities, and circumstances (voluntary vs. involuntary commitment).
- History of prior mental health treatment — types of therapy, duration, and perceived effectiveness.
- Current mental health symptoms — a brief symptom checklist covering depression, anxiety, panic attacks, flashbacks or nightmares, racing thoughts, grandiosity, hallucinations, paranoia, and difficulty concentrating.
- Trauma history screening — whether the client has experienced physical abuse, sexual abuse, emotional abuse, combat, serious accidents, violent crime, or other traumatic events. This does not need to be a detailed trauma narrative at intake — it is a screen that alerts the treatment team to the presence of trauma so that trauma-informed approaches can be integrated from the start.
- Suicide and self-harm assessment — current and historical suicidal ideation, suicide attempts with method and medical severity, non-suicidal self-injury, and current safety plan if one exists.
The clinical rationale for robust dual-diagnosis screening at intake is straightforward: if you treat the substance use disorder without addressing the underlying depression, PTSD, or anxiety, the client will relapse. And if you refer the client to a separate mental health provider without communicating the substance use history — which requires Part 2-compliant consent — the mental health provider is working blind. The intake form is where integrated treatment begins.
Medication-Assisted Treatment (MAT) Documentation
Medication-assisted treatment — the use of FDA-approved medications in combination with counseling and behavioral therapies — is the evidence-based standard of care for opioid use disorder and alcohol use disorder. The three primary MAT medications each carry their own intake documentation requirements:
Buprenorphine (Suboxone, Sublocade, Zubsolv)
If your program prescribes buprenorphine for opioid use disorder, the intake form needs to document: the client's opioid use history with sufficient detail to confirm an opioid use disorder diagnosis, current opioid tolerance level (which affects induction dosing), time since last opioid use (premature buprenorphine induction can precipitate withdrawal), history of prior buprenorphine treatment and reason for discontinuation if applicable, history of buprenorphine diversion or misuse, and the client's willingness to participate in counseling alongside medication.
Since the elimination of the X-waiver requirement in 2023, any DEA-registered practitioner with a Schedule III authority can prescribe buprenorphine for opioid use disorder. This expanded access means more programs are incorporating buprenorphine into their service offerings, and the intake form must be updated to capture the clinical data that supports safe prescribing.
Methadone
Methadone for opioid use disorder can only be dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs). OTP intake requirements are governed by 42 CFR Part 8 in addition to Part 2, and include: documentation of at least one year of opioid addiction (with exceptions for pregnant patients, recently incarcerated individuals, and patients previously treated with methadone), a physical examination within the past 30 days, tuberculosis screening, and pregnancy testing for individuals of childbearing potential. The intake form for an OTP is among the most heavily regulated in healthcare.
Naltrexone (Vivitrol)
Naltrexone blocks opioid receptors and is used for both opioid use disorder and alcohol use disorder. The critical intake documentation point for naltrexone is confirming that the client has been opioid-free for a minimum of 7-10 days (for short-acting opioids) or 10-14 days (for long-acting opioids like methadone). Administering naltrexone to a client with opioids in their system will precipitate severe withdrawal. The intake form must document the date and time of last opioid use, and many programs require a naloxone challenge test or urine drug screen confirmation before naltrexone initiation.
For all MAT medications, the intake form should also capture: informed consent specific to the medication (risks, benefits, alternatives, expected duration of treatment), agreement to comply with drug testing requirements, agreement to participate in counseling as a condition of receiving medication, and authorization to coordinate care with other prescribers.
Court-Ordered and Mandated Treatment Intake
A substantial portion of clients entering substance abuse treatment arrive under some form of legal mandate. The intake form must accommodate these clients with additional documentation sections that voluntary clients do not need:
- Court order or mandate documentation: A copy of the court order, plea agreement, probation condition, DUI/DWI sentence, or other legal document specifying the treatment requirement. The intake form should include fields to record the referring court, judge, docket number, probation officer name and contact information, and the specific treatment requirements (duration, frequency, type of program, drug testing requirements).
- Reporting obligations: Court-ordered clients typically require the treatment program to submit progress reports to the probation officer, court, or other referring entity. Under 42 CFR Part 2, this reporting requires specific written consent from the client. The consent form must name the recipient, describe what information will be reported (attendance, drug test results, treatment compliance, discharge status), and explain the consequences of the client revoking consent (which may include violation of the court order).
- Drug court participants: Drug court programs have their own reporting schedules, phase structures, and compliance standards. The intake form for a drug court participant should capture the current phase, the drug court coordinator's contact information, the specific behavioral benchmarks required for phase advancement, and the sanction schedule for noncompliance.
- Professional licensing board mandates: Physicians, nurses, attorneys, pilots, and other licensed professionals may be mandated to treatment by their licensing board or a professional monitoring program (such as a Physician Health Program). These mandates often have specific treatment requirements, documentation standards, and direct communication channels between the treatment program and the monitoring entity. The intake form should capture the monitoring program contact and the specific terms of the monitoring agreement.
- Child protective services (CPS) involvement: Clients referred by CPS may have treatment completion as a requirement for reunification with their children. The intake form should document the CPS caseworker's contact information, the case plan requirements related to substance abuse treatment, and the reporting schedule. Consent for communication with CPS must be obtained under Part 2, and the emotional weight of potential family separation makes this a particularly sensitive intake conversation.
The critical practice point for mandated clients is that treatment motivation is often external at intake — the client is there because they have to be, not because they want to be. The intake form cannot change this, but it can document the client's stage of change accurately, capture the legal requirements so the treatment team knows exactly what compliance looks like, and create a record that protects the program if the client later disputes what was communicated at intake.
Relapse History and Trigger Identification
For clients who have prior treatment experience — which is the majority in most substance abuse treatment settings — the relapse history section of the intake form provides some of the most clinically valuable data available at the start of treatment.
- Number of prior treatment episodes — and for each: the type of treatment (detox, residential, PHP, IOP, outpatient, 12-step), the duration completed, whether the client completed or left AMA (against medical advice), and the approximate length of sobriety achieved after each episode.
- Longest period of sustained sobriety — and what the client was doing differently during that period. This question is often more clinically useful than the relapse history itself, because it identifies what has actually worked for this client in the past.
- Relapse triggers — a checklist of common triggers (stress, interpersonal conflict, social pressure, emotional states such as loneliness or boredom, physical pain, exposure to substances, celebration or positive events, specific people, specific locations, specific times of day or year) with an open-ended field for triggers the client identifies that are not on the list.
- Relapse pattern — whether relapses have been sudden (impulsive use after a triggering event) or gradual (a slow erosion of recovery behaviors over days or weeks before actual use). This distinction is clinically significant because it determines whether relapse prevention planning should focus on impulse control strategies or on monitoring early warning signs of behavioral drift.
- Recovery capital inventory — what resources, skills, and supports the client has that support recovery: stable housing, employment, sober social network, sponsor or recovery coach, active 12-step or mutual aid involvement, family support, coping skills learned in prior treatment, hobbies or meaningful activities that do not involve substance use.
Clients who have been through treatment multiple times often experience shame about their relapse history. The intake form should frame these questions in a way that communicates that relapse is a clinical data point — not a moral failure — and that understanding the pattern is the foundation for building a more effective plan this time.
Social Support Network and Sober Living Assessment
ASAM Dimension 6 — Recovery/Living Environment — is frequently the dimension that makes or breaks treatment success, and it is the dimension most often underassessed at intake. The intake form should capture:
- Current living situation: Own home, rental, sober living facility, shelter, homeless, incarcerated, living with family, living with partner. Whether the client has stable housing to return to after residential treatment, or whether discharge planning needs to include a housing component.
- Household composition: Who lives in the home, including whether anyone in the home currently uses substances. A client returning to a household where a partner or roommate is actively using faces a recovery environment that outpatient treatment alone may not be sufficient to overcome.
- Dependent children: Ages, custody status, current caregiving arrangements during treatment. This affects treatment scheduling (outpatient clients need appointment times compatible with school pickup), residential treatment feasibility, and coordination with child protective services if involved.
- Employment status: Currently employed (full-time, part-time, self-employed), unemployed, on disability, on leave. Whether the employer is aware of the treatment and whether job protection (such as FMLA) has been secured.
- Transportation: Whether the client has reliable transportation to treatment. This is a practical barrier that kills treatment compliance more often than lack of motivation does.
- Legal issues: Pending charges, probation/parole status, outstanding warrants, family court proceedings. Legal stressors affect treatment engagement and may create scheduling conflicts with court appearances.
- Financial situation: Income sources, outstanding debts, financial stressors. Financial instability is both a relapse trigger and a barrier to sustained treatment participation.
- Social support quality: Whether the client has relationships with people who support their recovery, whether the client's primary social network involves substance use, whether the client has access to mutual aid meetings or a recovery community.
The sober living assessment is especially critical for clients transitioning from residential to outpatient levels of care, or for clients whose home environment was a primary contributor to their substance use. Documenting these factors at intake ensures that discharge planning begins on day one — not in the last week of treatment when housing and support gaps are suddenly urgent.
Drug Testing Consent and Chain of Custody Documentation
Drug testing is a standard component of substance abuse treatment, and the intake form must establish the consent and procedural framework for it at the outset. This section should cover:
- Consent to drug testing: The client's written consent to submit to urine, oral fluid, or hair follicle drug testing at the program's discretion, including random testing without advance notice.
- Testing methodology: Whether the program uses point-of-care (rapid) immunoassay testing, laboratory-confirmed testing (GC-MS or LC-MS/MS), or both. Whether positive results on rapid screens will be sent for confirmatory testing before clinical or legal action is taken.
- Chain of custody procedures: For court-ordered clients or clients in professional monitoring programs, drug test results may be used as legal evidence. The intake form should document whether chain-of-custody procedures will be followed (observed collection, tamper-evident seals, laboratory confirmation, Medical Review Officer review) and whether the client consents to these procedures.
- Observed vs. unobserved collection: Whether urine collections will be directly observed to prevent substitution or adulteration, and the client's consent to observed collection. This is a sensitive issue that should be addressed transparently at intake rather than becoming a surprise during treatment.
- Consequences of positive results: What happens clinically (treatment plan modification, level-of-care review) and administratively (reporting to court, probation, licensing board, employer) when a client tests positive. Clients — especially mandated clients — need to understand these consequences at intake, not after the first positive test.
- Consequences of refusal or adulteration: Whether a refused test or an adulterated/substituted specimen will be treated as a positive result for reporting purposes.
For Part 2-covered programs, drug test results are protected substance use records. Disclosure of results to courts, probation officers, employers, or other outside parties requires the same Part 2-compliant written consent discussed earlier. The drug testing consent form and the Part 2 disclosure consent form should be cross-referenced at intake so the client understands the connection between consenting to drug testing and consenting to the disclosure of results.
Insurance Verification and Parity Compliance
Insurance verification at intake is a financial necessity, but in substance abuse treatment it also intersects with the Mental Health Parity and Addiction Equity Act (MHPAEA). This federal law requires that insurance plans offering mental health and substance use disorder benefits provide those benefits at parity with medical/surgical benefits — meaning the same deductibles, copays, visit limits, prior authorization requirements, and medical necessity criteria.
The intake form should capture:
- Insurance information: Primary and secondary insurance, policy number, group number, subscriber name and relationship to client, insurance company phone number for provider services.
- Prior authorization status: Whether prior authorization has been obtained for the recommended level of care, the authorization number, and the number of days or sessions authorized.
- Benefits verification: Deductible (amount and how much has been met), copay or coinsurance for substance abuse treatment, out-of-pocket maximum, and any visit or day limits.
- Parity documentation: If the insurance company applies limits, prior authorization requirements, or medical necessity criteria to substance abuse treatment that it does not apply to comparable medical/surgical treatments, this may be a parity violation. Documenting the insurer's stated requirements at intake creates a record that can support a parity complaint if needed.
- Financial responsibility agreement: What the client will owe after insurance, payment plan options, and the consequences of nonpayment. For clients without insurance, whether the program offers sliding-scale fees, accepts Medicaid, or has access to state-funded treatment slots.
Insurance verification is particularly important in substance abuse treatment because the authorization process is often iterative — payers may authorize an initial period at a given level of care and then require concurrent review for continued stay. The intake form establishes the baseline authorization, and the clinical documentation from that point forward supports each subsequent authorization request.
Family Involvement and Collateral Contact Consent
Substance use disorders affect families, and effective treatment often involves family members in some capacity — family therapy sessions, family education groups, multi-family groups, or at minimum communication with family members about the client's treatment progress. Under 42 CFR Part 2, none of this can happen without the client's written consent.
The intake form should include:
- Family contact information: Names, relationships, and contact information for immediate family members and significant others.
- Consent for family involvement in treatment: Whether the client authorizes the program to communicate with specific family members, and what information may be shared (attendance, general progress, treatment plan details, drug test results, discharge planning).
- Family history of substance use: Whether parents, siblings, or other close family members have histories of substance use disorder, alcohol use disorder, or addiction. Family history is a significant risk factor and is relevant to both the clinical assessment and psychoeducation components of treatment.
- Family dynamics assessment: Whether family relationships are supportive or enabling, whether there is current or historical domestic violence in the home, whether family members are willing to participate in family programming. A client whose family is actively sabotaging recovery (for example, a partner who uses substances in the home and undermines treatment compliance) presents a different clinical picture than a client whose family is engaged and supportive.
- Collateral contacts: Other individuals the treatment team may need to communicate with — sponsors, recovery coaches, clergy, attorneys, employers, teachers. Each contact requires a separate Part 2-compliant consent.
The family section of the intake form often reveals the relational dynamics that are sustaining the addiction. A client who lists no family contacts, or who refuses consent for any family communication, is communicating something clinically important — either that the family relationships are so damaged that contact would be harmful, or that the client is hiding the extent of their substance use from family members. Either way, it becomes part of the treatment picture.
Overdose History and Naloxone Access
With opioid overdose deaths remaining a leading cause of preventable death in the United States, every substance abuse intake form should include a dedicated overdose history and naloxone access section. This is not optional — it is a clinical safety imperative.
- Personal overdose history: Number of overdose events, substances involved in each, whether naloxone was administered, whether emergency medical services responded, whether the client was hospitalized, and whether the client required intubation or ICU care. Each overdose event is a significant clinical data point — a client with a history of multiple overdoses is at substantially higher risk for a fatal overdose than a client who has never overdosed.
- Witnessed overdose history: Whether the client has witnessed another person overdose, and the circumstances. Witnessing an overdose is both a traumatic event and a potential motivator for treatment.
- Current naloxone access: Whether the client currently possesses naloxone (Narcan), knows how to administer it, and whether household members or close contacts have been trained in naloxone administration.
- Naloxone prescribing and education: The intake process should include either prescribing or providing naloxone to every client with an opioid use disorder (and their family members), along with education on overdose recognition and naloxone administration. The intake form should document that this occurred.
- Overdose risk factors: Recent period of abstinence followed by return to use (reduced tolerance), polysubstance use (especially opioids combined with benzodiazepines or alcohol), history of intravenous use, solitary use, and use of substances of unknown potency (fentanyl-adulterated supply).
The intake form should also capture the client's overdose safety plan — whether they use alone, whether someone knows when they are using, whether they have access to fentanyl test strips, and whether they are willing to use naloxone or have someone available who can administer it. For clients who are not yet ready to commit to abstinence, this harm reduction information may be the most important safety data collected at intake.
Additional Sections for Comprehensive Documentation
Beyond the core sections above, a thorough substance abuse intake form may also include:
- Infectious disease screening: Risk assessment and/or testing for hepatitis B, hepatitis C, HIV, tuberculosis, and sexually transmitted infections. Intravenous drug use, needle sharing, and high-risk sexual behaviors associated with substance use all elevate infectious disease risk. Many state regulations require TB screening at admission to residential treatment programs.
- Gambling and behavioral addiction screening: Co-occurring gambling disorder, internet/gaming addiction, or compulsive sexual behavior may not surface unless specifically asked about. A brief screen at intake can identify these issues for inclusion in the treatment plan.
- Cultural and spiritual considerations: The client's cultural background, spiritual or religious beliefs and practices, preferred language, and whether these factors should be incorporated into treatment planning. Recovery frameworks like 12-step programs have a spiritual component that resonates with some clients and alienates others — knowing this at intake helps with treatment matching.
- Military and veteran status: Whether the client is an active-duty service member, veteran, or military family member. Veterans may be eligible for VA-funded treatment, may have service-connected trauma, and may have cultural considerations (military culture around help-seeking, chain-of-command confidentiality concerns) that affect treatment engagement.
- Strengths and recovery capital: What the client has going for them — not just their deficits. Education, employment skills, supportive relationships, prior periods of sobriety, hobbies, community involvement. Starting the intake with a deficit-only lens misses the resources that treatment can build on.
Structuring the Intake for Clinical Utility
A substance abuse intake form that covers all of the above will be a substantial document. The question is not whether to include these sections — they are all clinically and regulatory necessary — but how to organize them so the form is usable for both the client filling it out and the clinician reviewing it.
Several structural principles make the difference between an intake form that gets completed thoroughly and one that gets rushed through or skipped:
- Lead with rapport-building sections. Demographics, insurance, and basic contact information first. The substance use history, trauma screening, and safety assessment should come after the client has settled into the process.
- Use checkboxes and grids for prevalence screening. The substance-by-substance inventory, mental health symptom checklist, and relapse trigger checklist all work well as structured grids. Open-ended narrative questions should be reserved for areas where the client's own language is clinically important.
- Separate the consent forms. Treatment consent, Part 2 disclosure consents, drug testing consent, MAT-specific consent, and financial agreement should be separate documents within the intake packet, each with its own signature line and date. This is a regulatory best practice — a single omnibus consent form makes it harder to demonstrate that the client was informed about each specific element.
- Build in a clinician completion section. Some intake data — the CIWA or COWS score, vital signs, BAC, initial clinical impression, recommended level of care, and ASAM dimensional summary — should be filled out by the clinician during or immediately after the intake assessment, not by the client. Include a section at the end of the form for clinician-documented findings.
Putting It All Together
A well-designed substance abuse counseling intake form is a comprehensive clinical document that typically runs 10 to 16 pages when it includes all necessary sections and consent forms. That length is not a sign of overengineering — it is a reflection of the clinical complexity, regulatory requirements, and legal considerations that are unique to addiction treatment.
Every question on the form should earn its place by serving at least one of three purposes: informing the clinical assessment and treatment plan, satisfying a federal or state regulatory requirement, or protecting the client and the program in the event of a dispute, audit, or adverse outcome. Questions that do not meet any of these tests should be removed — but in substance abuse treatment, the list of questions that genuinely matter is long.
The intake form is also the first message a client receives about what treatment will be like. A form that is thorough, well-organized, and written in respectful language communicates that this program takes the work seriously and treats clients as whole people with complex lives — not as a diagnosis walking through the door. In addiction treatment, where trust is hard-won and easily lost, that first impression matters.
Professional intake forms for substance abuse counseling — ready to use
Fillable PDF intake form and client questionnaire covering substance use history, 42 CFR Part 2 compliance, ASAM level of care, MAT documentation, dual diagnosis screening, court-ordered treatment, drug testing consent, and relapse prevention.
Browse All Forms View Bundles